3SBio
3SBio is a leading, fully integrated, profitable biotechnology company focused on researching, developing, manufacturing and marketing.
Launch date
Employees
Market cap
€1.5b
Enterprise valuation
€1.3b (Public information from Sep 2024)
Share price
HKD5.66 1530.HK
Shenyang Liaoning (HQ)
Financials
Estimates*
CNY | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Revenues | 5.6b | 6.4b | 6.9b | 7.8b | 8.9b | 9.7b | 10.6b |
% growth | 5 % | 14 % | 7 % | 14 % | 14 % | 9 % | 10 % |
EBITDA | 1.6b | 2.3b | 2.8b | 2.8b | 3.1b | 3.4b | 3.7b |
% EBITDA margin | 29 % | 36 % | 40 % | 36 % | 35 % | 35 % | 34 % |
Profit | 836m | 1.7b | 1.9b | 1.5b | 2.0b | 2.3b | 2.5b |
% profit margin | 15 % | 26 % | 28 % | 20 % | 23 % | 23 % | 23 % |
EV / revenue | 2.7x | 2.1x | 3.0x | 2.4x | 1.4x | 1.1x | 0.7x |
EV / EBITDA | 9.4x | 5.7x | 7.3x | 6.5x | 4.0x | 3.0x | 2.0x |
R&D budget | 590m | 754m | 693m | 795m | - | - | - |
R&D % of revenue | 11 % | 12 % | 10 % | 10 % | - | - | - |
Source: Dealroom estimates
Date | Investors | Amount | Round |
---|---|---|---|
N/A | N/A | IPO | |
N/A | N/A | IPO | |
Total Funding | - |
Recent News about 3SBio
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by 3SBio
Editexited
exited
ACQUISITION by 3SBio Sep 2017